Targeting genetic changes in aggressive lymphoma for better treatment
Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma
This study is looking at how certain changes in genes on chromosome 18 can make diffuse large B-cell lymphoma (DLBCL) more aggressive, and it aims to create personalized treatments using new medicines that target these genetic markers to help improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10986115 on NIH RePORTER |
What this research studies
This research focuses on diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, which is often treated with chemotherapy and the anti-CD20 antibody, Rituximab. The study aims to identify genetic alterations on chromosome 18 that are linked to more aggressive forms of DLBCL, particularly focusing on the TCF4 and BCL2 genes. By using innovative protein-degrader molecules and inhibitors, the researchers hope to develop a precision medicine approach that tailors treatment based on these genetic markers, potentially improving outcomes for patients with this challenging disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with diffuse large B-cell lymphoma, particularly those with aggressive subtypes associated with genetic alterations on chromosome 18.
Not a fit: Patients with other types of lymphoma or those whose DLBCL does not exhibit the specific genetic changes being targeted may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with aggressive forms of DLBCL.
How similar studies have performed: Previous research has shown promise in targeting genetic alterations in various cancers, suggesting that this approach could be effective, although the specific targeting of 18q alterations in DLBCL is relatively novel.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Green, Michael Richard — University of Tx Md Anderson Can Ctr
- Study coordinator: Green, Michael Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.